Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. dominated the market today, gaining €14.44 (19.390%).
With 24 Buy predictions and 1 Sell predictions Halozyme Therapeutics Inc. is one of the favorites of our community.
With a target price of 91 € there is a slightly positive potential of 2.04% for Halozyme Therapeutics Inc. compared to the current price of 89.18 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 19.390% | 3.016% | 5.467% | 39.230% | 27.065% | 93.152% | 116.328% |
| Ligand Pharmaceuticals | -3.820% | 3.968% | -6.429% | 123.932% | 57.831% | 329.508% | 184.103% |
| United Therapeutics | -0.580% | 1.359% | -3.365% | 75.379% | 8.191% | 115.424% | 154.011% |
| Ionis Pharmaceuticals Inc. | 1.990% | 2.294% | -35.011% | 35.377% | -30.459% | 30.950% | 43.169% |
Comments
Halozyme Therapeutics (HALO) had its price target raised by TD Cowen from $96.00 to $105.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its price target raised by HC Wainwright from $95.00 to $115.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
Halozyme Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Halozyme Therapeutics, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 48% year over year to $481 million, while royalty revenue increased
LifeMD Q2 Earnings Call Highlights
Key Points
- Interested in LifeMD, Inc.? Here are five stocks we like better.
- Q2 profitability missed expectations: LifeMD reported $47.3 million in revenue and an adjusted EBITDA loss of about
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise